April 28, 2017 / 1:43 PM / 4 months ago

BRIEF-Genmab announces new late stage combination study of Daratumumab in multiple myeloma

April 28 (Reuters) - Genmab A/S:

* Genmab announces new phase III combination study of Daratumumab in multiple myeloma

* Study is expected to start in Q2 2017 and is designed to confirm results from MMY1001 study

* Prescription drug user fee act date of June 17, 2017 for Daratumumab

* Janssen Research with European myeloma network plans to start phase III study of Daratumumab in relapsed and refractory multiple myeloma Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below